Louisiana 2024 2024 Regular Session

Louisiana House Bill HB813 Engrossed / Bill

                    HLS 24RS-1905	ENGROSSED
2024 Regular Session
HOUSE BILL NO. 813
BY REPRESENTATIVE EDMONSTON
DRUGS/PRESCRIPTION:  Provides relative to prescribing, administering, and dispensing
of drugs for off-label use
1	AN ACT
2To enact R.S. 37:1704, relative to prescribing, administering, and dispensing of drugs by
3 certain licensed healthcare professionals; to provide for prescription, administration,
4 and dispensing of certain drugs for off-label use by healthcare professionals with
5 prescriptive authority; and to provide for related matters.
6Be it enacted by the Legislature of Louisiana:
7 Section 1.  R.S. 37:1704 is hereby enacted to read as follows:
8 ยง1704.  Prescription, administration, and dispensing of FDA-approved drugs for
9	off-label use
10	A.  As used in this Section, the following terms mean:
11	(1)  "FDA" means the United States Food and Drug Administration.
12	(2)  "Off-label use" means the use of a prescription drug for an indication for
13 which it has not been approved by the FDA or the use of such drug in an age group,
14 dosage, or route of administration that has not been approved by the FDA.
15	B.  No licensing board or commission created by the provisions of this Title
16 shall prohibit or restrict the prescribing, administering, or dispensing for an off-label
17 use of a drug that has been approved for a specific use by the FDA.
Page 1 of 2
CODING:  Words in struck through type are deletions from existing law; words underscored
are additions. HLS 24RS-1905	ENGROSSED
HB NO. 813
DIGEST
The digest printed below was prepared by House Legislative Services.  It constitutes no part
of the legislative instrument.  The keyword, one-liner, abstract, and digest do not constitute
part of the law or proof or indicia of legislative intent.  [R.S. 1:13(B) and 24:177(E)]
HB 813 Engrossed 2024 Regular Session	Edmonston
Abstract:  Provides that no healthcare professional licensing board of the state shall prohibit
or restrict the prescribing, administering, or dispensing of drugs for off-label use.
Present law provides for licensure and regulation by the state of various types of healthcare
professionals.
Proposed law retains present law and stipulates that no healthcare professional licensing
board or commission shall prohibit or restrict the prescribing, administering, or dispensing
for an off-label use of a drug that has been approved for a specific use by the U.S. Food and
Drug Administration (FDA).
Proposed law defines "off-label use", for purposes of proposed law, as the use of a
prescription drug for an indication for which it has not been approved by the FDA or the use
of such drug in an age group, dosage, or route of administration that has not been approved
by the FDA.
(Adds R.S. 37:1704)
Summary of Amendments Adopted by House
The Committee Amendments Proposed by House Committee on Health and Welfare to
the original bill:
1. Remove the La. Dept. of Health from the list of entities prohibited from making
rules limiting off-label use of drugs approved by the FDA.
Page 2 of 2
CODING:  Words in struck through type are deletions from existing law; words underscored
are additions.